Comparative pharmacokinetics of rVIII-SingleChain and octocog alfa (Advate®) in patients with severe haemophilia A

Haemophilia

Volumn 22, Issue 5, 2016, Pages 730-738

  Klamroth, R ^a   Simpson, M ^b   von Depka Prondzinski, M ^c   Gill, J C ^d   Morfini, M ^e   Powell, J S ^f   Santagostino, E ^g   Davis, J ^h   Huth Kuhne A ⁱ   Leissinger, C ^j   Neumeister, P ^k   Bensen Kennedy, D ^l   Feussner, A ^m   Limsakun, T ^l   Zhou, M ^l   Veldman, A ^m   St Ledger, K ^l   Blackman, N ^l   Pabinger, I ⁿ  

^a Vivantes Klinikum   (Germany)

^b RUSH UNIVERSITY MEDICAL CENTER   (United States)

^c Werlhof Institut   (Germany)

^d BLOOD RESEARCH INSTITUTE   (United States)

^e Azienda Ospedaliero Universitaria di Careggi   (Italy)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^h UNIVERSITY OF MIAMI   (United States)

ⁱ SRH Kurpfalzkrankenhaus und Hamophiliezentrum   (Germany)

^j The Louisiana Center for Bleeding and Clotting Disorders   (United States)

^k MEDICAL UNIVERSITY OF GRAZ   (Austria)

^l CSL Behring   (United States)

^m CSL BEHRING GMBH   (Germany)

ⁿ MEDICAL UNIVERSITY OF VIENNA   (Austria)

more..

Author keywords

clearance; factor VIII; haemophilia A; half life; pharmacokinetics; von Willebrand factor

Indexed keywords

HEMOSTATIC AGENT; RECOMBINANT BLOOD CLOTTING FACTOR 8; RECOMBINANT BLOOD CLOTTING FACTOR 8 SINGLE CHAIN; UNCLASSIFIED DRUG;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; DISEASE SEVERITY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFECT; DRUG HALF LIFE; DRUG TOLERABILITY; HEMOPHILIA A; HUMAN; MALE; MAXIMUM PLASMA CONCENTRATION; MEAN RESIDENCE TIME; PRIORITY JOURNAL; TIME TO MAXIMUM PLASMA CONCENTRATION;

EID: 84990242425     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/hae.12985     Document Type: Article

References (23)

1. Dumont JA, Liu T, Low SC et al. Prolonged activity of a recombinant factor VIII-Fc fusion protein in hemophilia A mice and dogs. Blood 2012; 119: 3024–30.
2. Stennicke HR, Kjalke M, Karpf DM et al. A novel B-domain O-glycoPEGylated FVIII (N8-GP) demonstrates full efficacy and prolonged effect in hemophilic mice models. Blood 2013; 121: 2108–16.
3. Tiede A, Brand B, Fischer R et al. Enhancing the pharmacokinetic properties of recombinant factor VIII: first-in-human trial of glycoPEGylated recombinant factor VIII in patients with hemophilia A. J Thromb Haemost 2013; 11: 670–8.
4. Mahlangu J, Powell J, Ragni MV et al. Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A. Blood 2014; 123: 317–25.
5. Schulte S. Innovative coagulation factors: albumin fusion technology and recombinant single-chain factor VIII. Thromb Res 2013; 13(Suppl. 2): S2–6.
6. Zollner S, Raquet E, Claar P et al. Non-clinical pharmacokinetics and pharmacodynamics of rVIII-SingleChain, a novel recombinant single-chain factor VIII. Thromb Res 2014; 134: 125–31.
7. Dasgupta S, Repesse Y, Bayry J et al. VWF protects FVIII from endocytosis by dendritic cells and subsequent presentation to immune effectors. Blood 2007; 109: 610–2.
8. Delignat S, Repesse Y, Navarrete AM et al. Immunoprotective effect of von Willebrand factor towards therapeutic factor VIII in experimental haemophilia A. Haemophilia 2012; 18: 248–54.
9. Zollner SB, Raquet E, Mueller-Cohrs J et al. Preclinical efficacy and safety of rVIII-SingleChain (CSL627), a novel recombinant single-chain factor VIII. Thromb Res 2013; 132: 280–7.
10. ClinicalTrials.gov. An open-label safety, efficacy and pharmacokinetic study of a recombinant FVIII compared to recombinant human antihemophilic FVIII in patients with severe hemophilia A. NCT01486927. https://clinicaltrials gov/ct2/show/NCT01486927?term=NCT01486927&rank=1. Accessed March 20, 2015.
11. Duncan E, Collecutt M, Street A. Nijmegen-Bethesda assay to measure factor VIII inhibitors. Methods Mol Biol 2013; 992: 321–33.
12. Kasper CK. Diagnosis and management of inhibitors to factors VIII and IX: An introductory discussion for physicians. http://www1.wfh.org/publication/files/pdf-1178.pdf. Accessed July 29, 2014.
13. Sandberg H, Kannicht C, Stenlund P et al. Functional characteristics of the novel, human-derived recombinant FVIII protein product, human-cl rhFVIII. Thromb Res 2012; 130: 808–17.
14. Schmidbauer S, Witzel R, Robbel L et al. Physicochemical characterisation of rVIII-SingleChain, a novel recombinant single-chain factor VIII. Thromb Res 2015; 136: 388–95.
15. Powell JS, Pasi KJ, Ragni MV et al. Phase 3 study of recombinant factor IX Fc fusion protein in hemophilia B. N Engl J Med 2013; 369: 2313–23.
16. Santagostino E, Negrier C, Klamroth R et al. Safety and pharmacokinetics of a novel recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in hemophilia B patients. Blood 2012; 120: 2405–11.
17. Powell JS, Josephson NC, Quon D et al. Safety and prolonged activity of recombinant factor VIII Fc fusion protein in hemophilia A patients. Blood 2012; 119: 3031–7.
18. Coyle TE, Reding MT, Lin JC, Michaels LA, Shah A, Powell J. Phase I study of BAY 94-9027, a PEGylated B-domain–deleted recombinant FVIII with an extended half-life, in subjects with hemophilia A. J Thromb Haemost 2014; 12: 488–96.
19. Konkle BA, Stasyshyn O, Chowdary P et al. Pegylated, full-length, recombinant factor VIII for prophylactic and on-demand treatment of severe hemophilia A. Blood 2015; 126: 1078–85.
20. Jimenez-Yuste V, Auerswald G, Benson G et al. Achieving and maintaining an optimal trough level for prophylaxis in haemophilia: the past, the present and the future. Blood Transfus 2014; 12: 314–9.
21. Martinowitz U, Bjerre J, Brand B et al. Bioequivalence between two serum-free recombinant factor VIII preparations (N8 and ADVATE(R))–an open-label, sequential dosing pharmacokinetic study in patients with severe haemophilia A. Haemophilia 2011; 17: 854–9.
22. Weiss HJ, Sussman II, Hoyer LW. Stabilization of factor VIII in plasma by the von Willebrand factor. Studies on posttransfusion and dissociated factor VIII and in patients with von Willebrand's disease. J Clin Invest 1977; 60: 390–404.
23. Lacroix-Desmazes S, Navarrete AM, Andre S, Bayry J, Kaveri SV, Dasgupta S. Dynamics of factor VIII interactions determine its immunologic fate in hemophilia A. Blood 2008; 112: 240–9.